LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

M A A Mamun; Yu Zhang; Jin-Yuan Zhao; Dan-Dan Shen; Ting Guo; Yi-Chao Zheng; Li-Juan Zhao; Hong-Min Liu

doi:10.1186/s12929-023-00952-0

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

J Biomed Sci. 2023 Jul 31;30(1):60. doi: 10.1186/s12929-023-00952-0.

Authors

M A A Mamun¹, Yu Zhang¹, Jin-Yuan Zhao¹, Dan-Dan Shen^{2

3}, Ting Guo¹, Yi-Chao Zheng¹, Li-Juan Zhao^{4

5}, Hong-Min Liu⁶

Affiliations

¹ Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, China.
² Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
³ Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
⁴ Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, China. xiaoye1695651408@163.com.
⁵ State Key Laboratory of Esophageal Cancer Prevention and Treatment, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, China. xiaoye1695651408@163.com.
⁶ Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, China. liuhm@zzu.edu.cn.

Abstract

Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.

Keywords: Epigenetic TME regulation; Immune checkpoint blockade; Immunosuppression; LSD1; Tumor microenvironment.

Publication types

Review

MeSH terms

Epigenesis, Genetic
Histone Demethylases / genetics
Histones / metabolism
Humans
Neoplasms* / drug therapy
Tumor Microenvironment*

Substances

Histones
Histone Demethylases

Grants and funding

2018YFE0195100/National Key Research Program